Gene Therapy to Target CD22 for Oncology is under clinical development by Kecellitics Biotech and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). According to GlobalData, Phase II drugs for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy to Target CD22 for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target CD22 for Oncology overview
Gene therapy was under development for the treatment of relapsed and refractory B cell derived acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL) and b-cell non-Hodgkin lymphoma. The therapeutic candidate comprises of autologous T cells genetically engineered to express chimeric antigen receptor that targets CD22. It is administered through parenteral route.
For a complete picture of Gene Therapy to Target CD22 for Oncology’s drug-specific PTSR and LoA scores, buy the report here.